Europe
Effective July 2007 The EMEA has recommended the withdrawal of themarketing authorization for medicinal
productscontaining veralipride. The EMEA’s Committee forMedicinal Products for Human Use (CHMP)concluded that the risks of veralipride (psychiatric andmovement disorders) in the treatment of hot flushesassociated with menopause in women are greaterthan its benefits and therefore recommended that themedicine should be taken off the market.Reference:
Press Release. EMEA, 23 July 2007
Effective July 2007 The EMEA has recommended the withdrawal of themarketing authorization for medicinal
productscontaining veralipride. The EMEA’s Committee forMedicinal Products for Human Use (CHMP)concluded that the risks of veralipride (psychiatric andmovement disorders) in the treatment of hot flushesassociated with menopause in women are greaterthan its benefits and therefore recommended that themedicine should be taken off the market.Reference:Press Release. EMEA, 23 July 2007
(http://www.emea.europa.eu/).
Europa
A partir de julio de 2007 la EMEA ha recomendado la retirada de la la autorización de comercialización de medicamentos que contiene veralipride.
Europa
A partir de julio de 2007 la EMEA ha recomendado la retirada de la la autorización de comercialización de medicamentos que contiene veralipride.
El Comité de la EMEA Medicamentos de Uso Humano (CHMP) llegó a la conclusión de que los riesgos de veralipride (psiquiátrico y los trastornos del movimiento) en el tratamiento de los sofocos asociados con la menopausia en las mujeres son mayores que sus beneficios y, por tanto, recomendó que la la medicina debe ser retirado del mercado.
Referencia:
Comunicado de Prensa. EMEA, 23 de julio de 2007 (http://www.emea.europa.eu/).
Referencia:
Comunicado de Prensa. EMEA, 23 de julio de 2007 (http://www.emea.europa.eu/).
No hay comentarios:
Publicar un comentario